UK +44 (0)1865 849841
Malaysia +603 2731 9335

Tag: liquid biopsies

Identifying biomarkers to track tumour burden in patient blood

There is a huge need to identify biomarkers to discern which metastatic colorectal cancer patients will benefit from treatment using Regorafenib. Despite being the latest approved drugs for the disease, Regorafenib has limited clinical efficacy and is associated with a number of side effects. However, a lot of patients are treated with Regorafenib as it is the only treatment available for patients who cannot receive anti-EGFR treatment due to K-RAS or BRAF mutation.

Read More

Immuno-oncology: A Saving Grace in Cancer Treatment

Technology is constantly changing the healthcare industry. Scientists and physicians are hard at work doing everything they can to enhance treatment options for patients battling many different types of diseases and cancers. Immuno-oncology (I-O) is a subarea of immunotherapy that is uncovering new ways that cancer can be treated. This type of treatment allows patients to participate in less invasive and taxing procedures all while finding newer treatment options on a more niche or case by case level. Immunotherapy treatments and supporting procedures are making their way into everyday cancer care to change the playing field for the better.

Read More

Nucleic Acid Quantification, Mutation Enrichment Technologies & Streamlining Genotyping

In just two years’ time, the digital PCR and qPCR market is set to be worth an estimated $4.94 billion. Dedicated sessions at the 4BIO Summit covered topics such as gene expression analysis, liquid biopsies and high-throughput screening. We have made the following presentation slides from Hendrik Emons, Naomi Park & Mike Makrigiorgos available.

Read More

Digital-Droplet PCR Gets Another ‘D’

Triple-d PCR enhances digital PCR sensitivity and precision for liquid biopsies

Digital-droplet PCR (ddPCR) has been implemented in diverse fields such as cancer biomarkers, viral load detection, prenatal screening, organ donor rejection, or library assessment for next generation sequencing. Detection of emerging resistance or minimal residual disease via ddPCR in liquid biopsies is also growing rapidly.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Archive